Scholar Rock Hits 20-Day High Amid Equity Awards
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 14 Nov 25
Source: Businesswire
Shares of Scholar Rock Holding Corporation (SRRK.O) reached a 20-day high today, reflecting positive momentum in the biopharmaceutical sector. The recent granting of 30,000 inducement equity awards to a new employee, including stock options priced at $29.37, has likely contributed to this upward movement. With the stock options set to vest over four years, investor confidence appears bolstered as the company prepares for upcoming earnings reports, despite a projected EPS decline of 33.33% year-over-year. Scholar Rock's focus on innovative treatments for neuromuscular diseases continues to attract attention, encouraging investors to monitor developments closely.
Analyst Views on SRRK
Wall Street analysts forecast SRRK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SRRK is 50.00 USD with a low forecast of 42.00 USD and a high forecast of 60.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Analyst Rating
11 Buy
0 Hold
0 Sell
Strong Buy
Current: 43.130
Low
42.00
Averages
50.00
High
60.00
Current: 43.130
Low
42.00
Averages
50.00
High
60.00
About SRRK
Scholar Rock Holding Corporation is a late-stage biopharmaceutical company. It is focused on advancing treatments for neuromuscular diseases, cardiometabolic disorders, and other serious diseases. Its transforming growth factor beta (TGFb) superfamily biology, its novel molecular mechanisms of growth factor activation enabled it to develop a proprietary platform for the discovery and development of monoclonal antibodies that locally and selectively target the precursor, or latent, forms of growth factors. Its product candidate, apitegromab, is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Apitegromab is being developed as a potential first muscle-targeted therapy for the treatment of SMA. Its products include SRK-439, SRK-181, SRK-373 and SRK-256. SRK-181 is a selective inhibitor of the activation of latent TGFb1, is being developed for the treatment of cancers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
